Annex C Biokinetic models and dose tables

Annals of the ICRP

Volumn 38, Issue 1-2, 2008, Pages 51-162

  ICRP, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149514344     PISSN: 01466453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.icrp.2008.08.005     Document Type: Article

References (215)

1. 11C]acetate as a tracer for non-invasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic and hyperaemic canine myocardium Circulation 81 1990 1594 1605
2. R.W. Leggett L.R. Williams A proposed blood circulation model for reference man Health Phys. 69 1995 187 201
3. P.D. Shreve M.D. Gross Imaging of the pancreas and related diseases with PET carbon-11-acetate J. Nucl. Med. 38 1997 1305 1310
4. P. Shreve P.C. Chiao H.D. Humes M. Schwaiger M.D. Gross Carbon-11-acetate PET imaging in renal disease J. Nucl. Med. 36 1995 1595 1601
5. 11C]acetate J. Nucl. Med. 38 1997 459 466
6. 11C]acetate J. Nucl. Med. 37 1996 521 529
7. 11C-acetate clearance in nasopharyngeal carcinoma Nucl. Med. Commun 20 1999 131 134
8. H.L. Atkins D.R. Christman J.S. Fowler Organic Radiopharmaceuticals Labeled with Isotopes of Short Half-Life. V. 18F-Labeled 5- and 6-Fluorotryptophan J. Nucl. Med. 13 1972 713 719
9. R. Bergmann P. Brust G. Kampf H.H. Coenen G. Stöcklin Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET Nucl. Med. Biol. 22 1995 475 481
10. 18F]fluorotyrosine, a new PET tracer of protein synthesis J. Nucl. Med. 30 1989 1367 1372
11. 18F-p-fluorophenylalanine for pancreas scanning Br. J. Radiol. 46 1973 277 288
12. 11C] methionine using whole body positron emission tomography Eur. J. Nucl. Med. 25 1998 629 633
13. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1987 149 150
14. T. Inoue K. Tomiyoshi T. Higuichi K. Ahmed M. Sarwar K. Aoyagi S. Amano S. Alyafei H. Zhang K. Endo Biodistribution studies on l-3-[fluorine-18]fluoro- α -methyl tyrosine: a potential tumor-detecting agent J. Nucl. Med. 39 1996 663 667
15. 123I]iodo- α -methyltyrosine Eur. J. Nucl. Med. 24 1997 1162 1166
16. 18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours J. Nucl. Med. 40 1999 331 338
17. 14C as a biological tracer Nature (Lond.) 267 1977 828 832
18. 2 in long-term studies of fat metabolism Appl. Radiat. Isot. 47 1996 417 422
19. 75Se-labelled amino acids Appl. Radiat. Isot. 52 2000 911 922
20. 18F for pancreas scanning Radiopharmaceuticals and Labelled Compounds Vol. I 1973 IAEA Vienna 441 443
21. 18F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice Nucl. Med. Biol. 26 1999 259 265
22. 18F]fluoroethyl)- l -tyrosine for tumor imaging J. Nucl. Med. 40 1999 205 212
23. 11C]methylspiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice J. Nucl. Med. 25 1984 1222 1227
24. L. Farde H. Hall E. Ehrin G. Sedvall Quantitative analysis of D2 dopamine receptor binding in the living human brain Science 231 1986 258 261
25. 2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients Psychopharmacology 133 1997 394 404
26. 11C]carfentanil binding to opiate receptors in humans by positron emission tomography J. Cereb. Blood Flow Metab. 10 1990 484 492
27. 11-C]raclopride (abstract) J. Nucl. Med. 5 Suppl. 1997 224
28. 1A receptors with PET: WAY-100635 and analogues Nucl. Med. Biol. 27 2000 463 466
29. 11C]DASB Eur. J. Nucl. Med. 27 2000 1719 1722
30. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
31. M. Iyo H. Namba K. Fukushi H. Shinotoh S. Nagatsuka T. Suhara Y. Sudo K. Suzuki T. Irie Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’s disease Lancet 349 1997 1805 1809
32. S. Kim H.N. Wagner Jr. V.L. Villemagne P-F. Kao R.F. Dannals H.T. Ravert T. Joh R.B. Dixon A.C. Civelik Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual detector system J. Nucl. Med. 38 1997 1726 1731
33. D.A. McClain C.C. Hug Jr. Intravenous fentanyl kinetics Clin. Pharmacol. Ther. 28 1980 106 114
34. 11C]NMPB), a muscarinic acetylcholine receptor antagonist Nucl. Med. Biol. 22 1995 13 17
35. B. Nosslin L. Johansson S. Leide-Svegborn J. Liniecki S. Mattsson D. Taylor A generic model for 11C-labelled radiopharmaceuticals for imaging receptors in the human brain, Presented at Workshop of Internal Dosimetry of Radionuclides in Oxford, 9–12 September 2002 Rad. Prot. Dosim. 105 2003 587 591
36. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain J. Cereb. Blood Flow Metab. 19 1999 1164 1173
37. 11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET Nucl. Med. Biol. 23 1996 627 634
38. 11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET J. Cereb. Blood Flow Metab. 8 1988 304 313
39. 11C-Ro 15 3890: PET study in human volunteers Human Psychopharmacol. 4 1989 215 220
40. 11C]WAY-100635 Med. Chem. Res. 5 1995 208 227
41. 11C]McN5652: a serotonin transporter radioligand J. Cereb. Blood Flow Metab. 19 1999 967 981
42. 11C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer’s disease J. Cereb. Blood Flow Metab. 21 2001 295 306
43. N.P. Verhoeff E.B. Buseman Sokole D. Hengst J.B. Stubbs E.A. van Royen Dosimetry of iodine-123 iomazenil in humans Eur. J. Nucl. Med. 20 1993 580 584
44. N.D. Volkow Y.-S. Ding J.S. Fowler G.-J. Wang J. Logan S.J. Gatley D.J. Schlyer N. Pappas A new PET ligand for the dopamine transporter: studies in human brain J. Nucl. Med. 36 1995 2162 2168
45. J.R. Votaw M.S. Ansari N. Scott Mason D. Schmidt T. de Paulis G. Holburn J.A. Clanton D.B. Votlaw R.G. Manning R.M. Kessler Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand J. Nucl. Med. 36 1995 1316 1321
46. G. Westera A. Buck C. Burger K.L. Leenders G.K. von Schultness A.P. Schubiger Carbon-11 and iodine-123 labelled iomazenil: a direct PET-SPECT comparison Eur. J. Nucl. Med. 23 1996 5 12
47. A.A. Wilson T. Inaba N. Fischer L.M. Dixon J. Nobrega J.N. DaSilva S. Houle Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: syntheses, radiosyntheses, and in vitro and in vivo evaluation Nucl. Med. Biol. 25 1998 769 776
48. 11C Eur. J. Nucl. Med. 1 1976 11 14
49. 11C]-methionine using whole body positron emission tomography Eur. J Nucl. Med. 25 1998 629 633
50. M.S. Berridge L.P. Adler P.S. Rao Radiation absorbed dose for O-15-butanol and O-15 water estimated by positron emission tomography J. Nucl. Med. 32 1991 1043
51. C. Brihaye J.C. Depresseux D. Comar Radiation dosimetry for bolus administration of oxygen-15 water J. Nucl. Med. 36 1995 651 656
52. Eichling, J.O., Bergman, S.R., Schwarz, S.W., Siegel, B.A. 1997. Equivalent dose estimates in adults for intravenously administered O-15 water. Unpublished; personal communication through S. Schwarz.
53. P. Herscovitch R.E. Carson M. Stabin A new kinetic approach to estimate the radiation dosimetry of flow-based radiotracers J. Nucl. Med. 34 1993 155P
54. T. Smith C. Tong A.A. Lammertsma Dosimetry of intravenously administered oxygen-15 labelled water in man: a model based on experimental human data from 21 subjects Eur. J. Nucl. Med. 21 1994 1126 1134
55. 18F]Fluorotyrosine, a new PET tracer of protein synthesis J. Nucl. Med. 30 1989 1367 1372
56. 18F-p-fluorophenylalanine for pancreas scanning Br. J. Radiol. 46 1973 277 288
57. ICRP Radiation dose to patients from radiopharmaceuticals ICRP Publication 53. Ann. ICRP 18 1–4 1987 149 150
58. ICRP Radiation dose to patients from radiopharmaceuticals Addendum 4 to ICRP Publication 2001 53
59. T. Inoue K. Tomiyoshi T. Higuichi K. Ahmed M. Sarwar K. Aoyagi S. Amano S. Alyafei H. Zhang K. Endo Biodistribution studies on l-3-[Fluorine-18]fluoro-α-methyl tyrosine: a potential tumor-detecting agent J. Nucl. Med. 39 1996 663 667
60. 123I]iodo- α -methyltyrosine Eur. J. Nucl. Med. 24 1997 1162 1166
61. 18F]1-Amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours J. Nucl. Med. 40 1999 331 338
62. 14C as a biological tracer Nature (Lond.) 267 1977 828 832
63. 2 in long-term studies of fat metabolism Appl. Radiat. Isot. 47 1996 417 422
64. 75Se-labelled amino acids Appl. Radiat. Isot. 52 2000 911 922
65. 18F for pancreas scanning Radiopharmaceuticals and Labelled Compounds Vol. I 1973 IAEA Vienna 441 443
66. 18F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice Nucl. Med. Biol. 26 1999 259 265
67. 18F]fluoroethyl)- l -tyrosine for tumor imaging J. Nucl. Med. 40 1999 205 212
68. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters Eur. J. Nucl. Med. 25 1998 24 30
69. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters: erratum Eur. J. Nucl. Med. 25 1998 458
70. K.L. Boundy L.R. Barnden C.C. Rowe M. Reid M. Kassiou A.G. Katsifis R.L. Lambrecht Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors J. Nucl. Med. 36 1995 1332 1338
71. 18F]FECNT J. Nucl. Med. 42 2001 376 381
72. 18F]Fluoroethylflumaazenil: a novel tracer for PET imaging of human benzodiazepine receptors Eur. J. Nucl. Med. 28 2001 1463 1470
73. 18F]-desmethoxyfallypride J. Nucl. Med. 44 2003 109 116
74. 123I]ADAM in healthy human subjects: preliminary results Eur. J. Nucl. Med. 30 2003 132 136
75. J.T. Kuikka K.A. Bergström A. Ahonen E. Länsimies The dosimetry of iodine-123 labelled 2 β -carbomethoxy-3β-(4-iodophenyl)tropane Eur. J. Nucl. Med. 21 1994 53 56
76. 18F]FFMZ): a potential GABA receptor ligand for PET Nucl. Med. Biol. 31 2004 291 295
77. P.D. Mozley J.T. Stubbs H-J. Kim W. McElgin S. Chumpradit M-P. Kung G. Romaniallo H.F. Kung Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT J. Nucl. Med. 36 1995 1322 1331
78. P.D. Mozley J.T. Stubbs H-J. Kim W. McElgin M-P. Kung S. Meegalla H.F. Kung Dosimetry of an iodine-123-labeled tropane to image dopamine transporters J. Nucl. Med. 37 1996 151 159
79. 11C]-labelled radiopharmaceuticals for imaging receptors in the human brain Rad. Prot. Dosim. 105 2003 587 591
80. Taylor, D.M., 2000a. Unpublished assessments.
81. C. van de Wiele F. De Vos J. De Sutter F. Dumont G. Slegers R.A. Dierkx H. Thierens Biokinetics and dosimetry of (iodine-123)-iodomethyl-N,N-dimethyltamoxifen, an (anti)oestrogen receptor radioligand Eur. J. Nucl. Med. 26 1999 1259 1264
82. N.P. Verhoeff E.B. Sokole M. Stabin D. Hengst H.F. Kung E.A. Van Royen A.G. Janssen Dosimetry of iodine-123 iodobenzamide in healthy volunteers Eur. J. Nucl. Med. 20 1993 747 752
83. N.P. Verhoeff E. Busemann Sokole D. Hengst J.B. Stubbs E.A. van Royen Dosimetry of iodine-123 iomazenil in humans Eur. J. Nucl. Med. 20 1993 580 584
84. 123I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor Eur. J. Nucl. Med. 27 2000 1326 1333
85. N.D. Volkow Y.S. Ding J.S. Fowler G.J. Wang J. Logan S.J. Gatley D.J. Schlyer N. Pappas A new PET ligand for the dopamine transporter: studies in human brain J. Nucl. Med. 36 1995 2162 2168
86. J.R. Votaw M.S. Ansari N. Scott Mason D. Schmidt T. de Paulis G. Holburn J.A. Clanton D.B. Votlaw R.G. Manning R.M. Kessler Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand J. Nucl. Med. 36 1995 1316 1321
87. 18F]FPS Nucl. Med. Biol. 30 2003 555 563
88. H.M. Deloar T. Fujiwara M. Shidahara T. Nakamura H. Watabe Y. Narita M. Itoh M. Miyake S. Watanuki Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging Eur. J. Nucl. Med. 25 1998 565 574
89. M.T. Hays G.M. Segall A mathematical model for the distribution of fluorodeoxyglucose in humans J. Nucl. Med. 40 1999 1358 1366
90. 18F-FDG. MIRD Dose Estimate Report No. 19 J. Nucl. Med. 43 2002 210 214
91. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
92. ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80 Ann. ICRP 28 3 1998
93. A.A. Meija T. Nakamura I. Masatoshi J. Hatazawa M. Mazaki S. Watanuki Estimation of absorbed doses in humans due to intraveneous administration of fluorine-18-fluorodeoxyglucose in PET studies J. Nucl. Med. 32 1991 699 706
94. 18F]-6-fluorodopa during positron emission tomography; elimination and metabolism in carbidopa treated subjects Life Sci. 39 1986 2243 2252
95. W.D. Brown T.R. Oakes O.T. DeJesus M.D. Taylor A.D. Roberts R.J. Nickles J.E. Holden Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment J. Nucl. Med. 39 1998 1884 1891
96. V. Dhawan A. Belakhlef W. Robeson T. Ishikawa C. Margouleff S. Takikawa T. Chaly K. Kazumata D. Margouleff D. Eidelberg Bladder wall radiation dose in humans from fluorine-18-FDOPA J. Nucl Med. 37 1996 1850 1852
97. 18F]fluoro-L-dopa J. Nucl. Med. 26 1985 931 935
98. W.D. Heiss K. Wienhard R. Wagner H. Lanfermann A. Thiel K. Herhoiz U. Pietrak F-DOPA as an amino acid tracer to detect brain tumors J Nucl. Med. 37 1996 1180 1182
99. 18F]fluoro-L-DOPA kinetics in positron emission tomography J. Nucl. Med. 33 1992 1472 1477
100. E. Lu E. Meyer H. Kuwabara Y. Ma M. Shiraishi A.C. Evans Reduction of radiation absorbed dose in F-18-DOPA PET studies by hydration-induced voiding J. Nucl. Med. 36 Suppl. 1995 98P
101. 18F]fluoro-L-DOPA and its metabolism in vivo – a critical review Nucl. Med. Biol. 19 1992 149 158
102. 18F]fluoro-L-dopa in rats, monkeys and humans Life Sci. 47 1990 149 157
103. G.-J. Meyer S.L. Waters H.H. Coenen A. Luxen B. Maziere B. Långström PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs) Eur. J. Nucl. Med. 22 1995 1420 1432
104. 18F]Fluoro-L-DOPA Eur. J Pharmacol. 257 1994 53 58
105. R. Bergmann P. Brust G. Kampf H.H. Coenen G. Stöcklin Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET Nucl. Med. Biol. 22 1995 475 481
106. 18F]fluorotyrosine, a new PET tracer of protein synthesis J. Nucl. Med. 30 1989 1367 1372
107. 18F-p-fluorophenylalanine for pancreas scanning Br. J. Radiol. 46 1973 277 288
108. 11C] methionine using whole body positron emission tomography Eur. J. Nucl. Med. 25 1998 629 633
109. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987 149 150
110. ICRP Radiation dose to patients from radiopharmaceuticals Addendum 4 to ICRP Publication 2001 53
111. T. Inoue K. Tomiyoshi T. Higuichi K. Ahmed M. Sarwar K. Aoyagi S. Amano S. Alyafei H. Zhang K. Endo Biodistribution studies on l-3-[Fluorine-18]fluoro- α -methyl tyrosine: a potential tumor-detecting agent J. Nucl. Med. 39 1996 663 667
112. 123I]iodo-α-methyltyrosine Eur. J. Nucl. Med. 24 1997 1162 1166
113. 18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours J. Nucl. Med. 40 1999 331 338
114. 14C as a biological tracer Nature (Lond.) 267 1977 828 832
115. 2 in long-term studies of fat metabolism Appl. Radiat. Isot. 47 1996 417 422
116. D.M. Taylor Generic models for radionuclide dosimetry: 11C, 18F or 75Se-labelled amino acids Appl. Radiat. Isot. 52 2000 911 922
117. 18F for pancreas scanning Radiopharmaceuticals and Labelled Compounds Vol. I 1973 IAEA Vienna 441 443
118. 18F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice Nucl. Med. Biol. 26 1999 259 265
119. 18F]fluoroethyl)- l -tyrosine for tumor imaging J. Nucl. Med. 40 1999 205 212
120. R. Taillefer S. Edell G. Innes J. Lister-James Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter trial investigators J. Nucl. Med. 41 2000 1214 1223
121. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
122. Liniecki, J., 1998. Private communication. Department of Nuclear Medicine, Medical University of Lodz, Lodz.
123. 99mTc-EC) distribution model in the organism Nucl. Med. Rev. 1 1998 29 32
124. 99mTc-EC) renal clearance determination error for the multiple- and single-sample methods Nucl. Med. Rev. 1 1998 33 40
125. 99mTc-N,N′-ethylene-1-dicysteine complex for dynamic kidney investigations Nucl. Med. Comm. 15 1994 628 635
126. 99mTc-ECD Eur. J. Nucl. Med. 24 1997 1245 1252
127. B.L. Holman R.S. Hellman S.J. Goldsmith I. Mena J. Leveille P.G. Gherardi J.L. Moretti A. Bischof-Delaloye T.C. Hill P.M. Rigo R.L. Van Heertum P.J. Ell U. Buell M.C. De Roo R.A. Morgan Biodistribution, dosimetry and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction J. Nucl. Med. 30 1989 1018 1024
128. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
129. J. Léveillé G. Demonceau R.C. Walovitch Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects J. Nucl. Med. 33 1992 480 484
130. S. Vallabhajosula R.E. Zimmerman M. Picard P. Stritzke I. Mena R.S. Hellman R.S. Tikofsky M.G. Stabin R.A. Morgan S.J. Goldsmith Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects J. Nucl. Med. 30 1989 599 604
131. M.C. Gerson J. Lukes E. Deutsch D. Biniakiewicz R.C. Rohe L.C. Washburn C. Fortman R.A. Walsh Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans J. Nucl. Cardiol. 1 1994 499 508
132. ICRP Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 1 Ann. ICRP 2 3/4 1979
133. ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 1 to ICRP Publication 53, in: Radiological protection in biomedical research. ICRP Publication 62 Ann. ICRP 22 3 1991
134. ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80 Ann. ICRP 28 3 1998
135. C. Rossetti G. Vanoli G. Paganelli M. Kwiatkowski F. Zito F. Colombo C. Bonino A. Carpinelli R. Casati K. Deutsch M. Marmion S.R. Woulfe F. Lunghi E. Deutsch F. Fazio Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12 J. Nucl. Med. 35 1994 1571 1580
136. A. Bischof Delaloye B. Delaloye Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J. Nucl. Med. 22 1995 571 580
137. K.E. Britton M. Granowska Radioimmunoscintigraphy in tumour identification Cancer Surv. 6 1987 247 267
138. A.J. Fishman B.A. Khaw H.N. Strauss Quo vadis radioimmune imaging J. Nucl. Med. 20 1989 1911 1915
139. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
140. M.J. Bronskill Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy Semin Nucl. Med. 13 1 1983 20 25
141. D. Eshima T. Fauconnier L. Eshima Radiopharmaceuticals for lymphoscintigraphy; including dosimetry and radiation considerations Semin. Nucl. med. 30 1 2000 25 32
142. A.J. Wilhelm G.S. Mijnhout .J. Franssen Eur. J.Nucl. Med. 26 1999 S36 S42
143. B. Higley F.W. Smith T. Smith H.G. Gemmell P.D. Gupta D.V. Gvozdanovic D. Graham D. Hinge J. Davidson A. Lahiri Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent J. Nucl. Med. 34 1993 30 38
144. ICRP Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 1 Ann. ICRP 2 3/4 1979
145. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
146. ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 1 to ICRP Publication 53, in: Radiological protection in biomedical research. ICRP Publication 62 Ann. ICRP 22 3 1991
147. 99mTc-P53 a new myocardial perfusion imaging agent A. Schlafke-Stelson E.E. Watson Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529 1992 Oak Ridge Associated Universities Oak Ridge, TN 467 481
148. A. Bischof Delaloye B. Delaloye Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J. Nucl. Med. 22 1995 571 580
149. K.E. Britton M. Granowska Radioimmunoscintigraphy in tumour identification Cancer Surv. 6 1987 247 267
150. A.J. Fishman B.A. Khaw H.N. Strauss Quo vadis radioimmune imaging J. Nucl. Med. 20 1989 1911 1915
151. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
152. 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy Acta Radiol. 35 1994 53 57
153. R.A.M.J. Claessens E.B. Koenders O.C. Boerman W.J. Oyen G.F. Borm J.W. van den Meer F.H. Corstens Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci Eur. J. Nucl. Med. 22 1995 212 219
154. E. Forssell Aronsson M. Fjälling O. Nilsson L.E. Tisell B. Wängberg H. Ahlman Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide J. Nucl. Med. 36 1995 7 12
155. 111In-DTPA-D-Phe-1-octreotide in patients with neuroendocrine tumours A.T. Schlafke-Stelson M.G. Stabin R.B. Sparks Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium ORISE 99-0164 1999 Oak Ridge Associated Universities Oak Ridge, TN 643 655
156. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
157. M. Koizumi K. Endo Y. Watanabe T. Saga H. Sakahara H. Konishi T. Yamamuro S. Toyama Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice Cancer Res. 49 1989 1752 1757
158. E.P. Krenning W.H. Bakker P.P.M. Kooij W.A.P. Breeman H.Y. Oei M. de Jong J.C. Reubi T.J. Visser C. Bruns D.J. Kwekkeboom A.E.M. Reijs P.M. van Hagen J.W. Koper S.W.J. Lamberts Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide J. Nucl. Med. 33 1992 652 658
159. 3)-octreotide: the Rotterdam experience with more than 1000 patients Eur. J. Nucl. Med. 20 1993 716 731
160. 111In-DTPA-D-Phe-1-octreotide in patients A.T. Schlafke-Stelson M.G. Stabin R.B. Sparks Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. ORISE 99-0164 1999 Oak Ridge Associated Universities Oak Ridge, TN 631 642
161. M.G. Stabin P.P. Kooij W.H. Bakker Radiation dosimetry for indium-111-pentetreotide J. Nucl. Med. 38 1997 1919 1922
162. M. Casteels V. Foulon G.P. Mannaerts P. van Veldhoven Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence Eur. J. Biochem. 270 2003 1619 1627
163. V. Caveliers P.R. Franken F.L. Florian H. Lou F.F. Knapp Jr. Intra-individual comparison of 3(R)-BMIPP and 3(S)-BMIPP isomers in humans J. Nucl. Med. 39 1998 1672 1675
164. F. De Geeter V. Caveliers I. Pansar A. Bossuyt P.R. Franken Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers J. Nucl. Med. 39 1998 1850 1856
165. R. Dudczak R. Schmoliner P. Angelberger F.F. Knapp M.M. Goodman Structurally modified fatty acids: clinical potential as tracers of metabolism Eur. J. Nucl. Med. 12 1986 S45 S48
166. 14C]oleate fat malabsorption breath test Appl. Radiat. Isot. 58 2003 517 526
167. F.F. Knapp Jr. J. Kropp Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: current status and future perspectives Eur. J. Nucl. Med. 22 1995 361 381
168. F.F. Knapp Jr. K.R. Ambrose M.M. Goodman New radioiodinated methyl-branched fatty acids for cardiac studies Eur. J. Nucl. Med. 12 Suppl 1986 S39 S44
169. F.F. Knapp Jr. P. Franken J. Kropp Cardiac SPECT with iodine-123-labeled fatty acids: evaluation of myocardial viability with BMIPP J. Nucl. Med. 36 1995 1022 1030
170. H.J. Machulla M. Marsmann K. Dutschka Biochemical concept and synthesis of a radioiodinated phenyl fatty acid for in vivo metabolic studies of the myocardium Eur. J. Nucl. Med. 5 1980 171 173
171. S.N. Reske 123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results Eur. Heart J. 6 Suppl B 1985 39 47
172. S.N. Reske H.J. Biersack K. Lackner H.J. Machulla R. Knopp N. Hahn C. Winkler Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography Nuklearmedizin 21 1982 249 253
173. G.W. Sloof F.C. Visser A. van Lingen J.J. Bax J. Eersels G.J. Teule F.F. Knapp Jr. Evaluation of heart-to-organ ratios of 123I-BMIPP and the dimethyl-substituted 123I-DMIPP fatty acid analogue in humans Nucl. Med. Commun. 18 1997 1065 1070
174. N. Tamaki K. Morita Y. Kuge E. Tsukamoto The role of fatty acids in cardiac imaging J. Nucl. Med. 41 2000 1525 1534
175. 123I-BMIPP) Kagu Igaku 28 1991 681 690
176. 123I-BMIPP fatty acid analog in healthy and CD36-deficient subjects J. Nucl. Med. 41 2000 1134 1138
177. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters, Eur J. Nucl. Med. 25 1998 24 30
178. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters: Erratum Eur. J. Nucl. Med. 25 1998 458
179. K.L. Boundy L.R. Barnden C.C. Rowe M. Reid M. Kassiou A.G. Katsifis R.L. Lambrecht Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors J. Nucl. Med. 36 1995 1332 1338
180. 18F]FECNT J Nucl Med. 42 2001 376 381
181. 18F]Fluoroethylflumaazenil: a novel tracer for PET imaging of human benzodiazepine receptors Eur. J. Nucl. Med. 28 2001 1463 1470
182. 18F]-desmethoxyfallypride J. Nucl. Med. 44 2003 109 116
183. 123I]ADAM in healthy human subjects: preliminary results Eur. J. Nucl. Med. 30 2003 132 136
184. J.T. Kuikka K.A. Bergström A. Ahonen E. Länsimies The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane Eur. J. Nucl. Med., 21 1994 53 56
185. 18F]FFMZ) a potential GABA receptor ligand for PET Nucl. Med. Biol. 31 2004 291 295
186. P.D. Mozley J.T. Stubbs H-J. Kim W. McElgin S. Chumpradit M-P. Kung G. Romaniallo H.F. Kung Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT J. Nucl. Med. 36 1995 1322 1331
187. P.D. Mozley J.T. Stubbs H-J. Kim W. McElgin M-P. Kung S. Meegalla H.F. Kung Dosimetry of an iodine-123-labeled tropane to image dopamine transporters J. Nucl. Med. 37 1996 151 159
188. 11C]-labelled radiopharmaceuticals for imaging receptors in the human brain Rad. Prot. Dosim. 105 2003 587 591
189. Taylor, D.M., 2000a. Unpublished assessments.
190. C. van de Wiele F. De Vos J. De Sutter F. Dumont G. Slegers R.A. Dierkx H. Thierens Biokinetics and dosimetry of (iodine-123)-iodomethyl-N,N-dimethyltamoxifen, an (anti)oestrogen receptor radioligand Eur. J. Nucl. Med. 26 1999 1259 1264
191. N.P. Verhoeff E.B. Sokole M. Stabin D. Hengst H.F. Kung E.A. van Royen A.G. Janssen Dosimetry of iodine-123 iodobenzamide in healthy volunteers Eur. J. Nucl. Med. 20 1993 747 752
192. N.P. Verhoeff E. Busemann Sokole D. Hengst J.B. Stubbs E.A. van Royen Dosimetry of iodine-123 iomazenil in humans Eur. J. Nucl. Med. 20 1993 580 584
193. 123I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor Eur. J. Nucl. Med. 27 2000 1326 1333
194. N.D. Volkow Y.-S. Ding J.S. Fowler G.-J. Wang J. Logan S.J. Gatley D.J. Schlyer N. Pappas A new PET ligand for the dopamine transporter: studies in human brain J. Nucl. Med. 36 1995 2162 2168
195. J.R. Votaw M.S. Ansari N. Scott Mason D. Schmidt T. de Paulis G. Holburn J.A. Clanton D.B. Votlaw R.G. Manning R.M. Kessler Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand J. Nucl. Med. 36 1995 1316 1321
196. 18F]FPS Nucl. Med. Biol. 30 2003 555 563
197. A. Bischof Delaloye B. Delaloye Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J. Nucl. Med. 22 1995 571 580
198. K.E. Britton M. Granowska Radioimmunoscintigraphy in tumour identification Cancer Surv. 6 1987 247 267
199. A.J. Fishman B.A. Khaw H.N. Strauss Quo vadis radioimmune imaging J. Nucl. Med. 20 1989 1911 1915
200. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
201. A. Bischof Delaloye B. Delaloye Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur J. Nucl. Med. 22 1995 571 580
202. K.E. Britton M. Granowska Radioimmunoscintigraphy in tumour identification Cancer Surv. 6 1987 247 267
203. A.J. Fishman B.A. Khaw H.N. Strauss Quo vadis radioimmune imaging J. Nucl. Med. 20 1989 1911 1915
204. ICRP Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18 1–4 1987
205. H.L. Atkins T.F. Budinger E. Lebowitz A.N. Ansari M.W. Greene R.G. Fairchild K.J. Ellis Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties J. Nucl. Med. 18 1977 133 140
206. R.D. Bartlett K.A. Lathrop P.F. Faulhaber P.V. Harper Transfer of thallous ion to and from gastrointestinal sections J. Nucl. Med. 25 1984 P92
207. C.T. Chen K.A. Lathrop P.V. Harper R.D. Bartlett V.J. Stark K.R. Fultz P.F. Faulhaber Quantitative measurement of long term in vivo thallium distribution in the human J. Nucl. Med. 24 1983 P50
208. M.R. Freeman N. Kanwar P.W. Armstrong The variability of thallium half life at rest as compared to exercise J. Nucl. Med. 27 1986 997
209. 67Ga after intravenous administration Int. J. Nucl. Med. Biol. 8 1981 211 213
210. P. Hosain F. Hosain Revision of gonadal radiation dose to man from thallium-201 Proceedings of the Third International Radiopharmaceutical Dosimetry Symposium, Oak Ridge 1980 (FDA 81-8166) 1981 Oak Ridge National Laboratories Oak Ridge, TN 333 345
211. W. Krahwinkel H. Herzog L.E. Feinendegen Pharmacokinetics of thallium-201 in normal individuals after routine myocardial scintigraphy J. Nucl. Med. 29 1988 1582 1586
212. 201Tl in human testes J. Nucl. Med. 45 2004 138 146
213. D.V. Rao B.J. Shepstone H.B. Wilkins R.W. Howell Kinetics and dosimetry of thallium-201 in human testes J. Nucl. Med. 36 1995 607 609
214. G. Samson F.J.Th. Wackers A.E. Becker E. Busemann Sokole J.B. van der Schoot Distribution of thallium-201 in man K. Oeff H.A.E. Schmidt Nuklearmedizin und biokybernetik Vol. 1 1978 Medico-informationsdienste Berlin 385 389
215. 201Tl-thallous chloride J. Nucl. Med. 46 2005 502 508